Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Gifu Municipal Hospital, Gifu, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:5City/State/Province:Gifu
Treatments:ChemotherapyHospital:Gifu Municipal Hospital
Drugs:Journal:Link
Date:Feb 2006

Description:

Patients: This Phase II study involved 61 patients (46 men, 15 women, median age 65 years) with advanced non-small-cell lung cancer. None of the patients had received treatment before the study.

Treatment: Treatment consisted of one chemotherapeutic agent: amrubicin.

Toxicity: Three patients experienced interstitial pneumonitis for which a causal relationship to amrubicin could not be denied, and two of them dies. In addition, grade 3-4 toxicities included neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, and vomiting.

Results: The median overall survival was 9.8 months. 17 of the 61 eligible patients had objective responses to amrubicin (1 complete response and 16 partial responses).





Back